IQIRVO 80mg film-coated tablets IPSEN ORIGINAL MEDICINE
Chemical substance: elafibranor
ATC code: A05AX06 • Alimentary tract and metabolism | Bile therapy | Other drugs for bile therapy
Active substance
Results for the substance elafibranor
1 result
About this active substance
Elafibranor is an experimental drug developed for the treatment of metabolic diseases such as dyslipidemia and non-alcoholic fatty liver disease (NAFLD). It works by activating PPAR receptors, which play a key role in regulating lipid and glucose metabolism.
Clinical studies have shown that elafibranor can reduce triglyceride and LDL cholesterol levels while increasing HDL cholesterol, making it a promising option for patients at high cardiovascular risk. Improvements in liver inflammation markers have also been observed in patients with NAFLD.
Reported side effects include nausea, fatigue, and, in rare cases, elevations in liver enzymes. It is essential for patients to be monitored during treatment to prevent potential complications.
Elafibranor represents an innovative direction in the treatment of metabolic diseases, offering hope for patients who do not respond to conventional therapies.
Clinical studies have shown that elafibranor can reduce triglyceride and LDL cholesterol levels while increasing HDL cholesterol, making it a promising option for patients at high cardiovascular risk. Improvements in liver inflammation markers have also been observed in patients with NAFLD.
Reported side effects include nausea, fatigue, and, in rare cases, elevations in liver enzymes. It is essential for patients to be monitored during treatment to prevent potential complications.
Elafibranor represents an innovative direction in the treatment of metabolic diseases, offering hope for patients who do not respond to conventional therapies.